More about
Sitagliptin
News
February 21, 2020
4 min read
Save
Sitagliptin reduces acute GVHD after peripheral blood stem cell transplantation
ORLANDO — The anti-diabetic medication sitagliptin significantly reduced incidence of acute graft-versus-host disease after myeloablative allogeneic peripheral blood stem cell transplantation, according to results of a prospective phase 2 study presented at TCT | Transplantation & Cellular Therapy Meetings.